Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
about
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsCarboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesisGuide to interpreting disease responses in chronic myeloid leukemia.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.Chronic Myelogenous Leukemia, Version 1.2014Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemiaMoving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.The choice of first-line chronic myelogenous leukemia treatment.Milestones and monitoring.Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report.The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaSecond-generation TKIs: which and when?Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Tyrosine kinase inhibitors in acute and chronic leukemias.Emerging drugs for acute lymphocytic leukemia.Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.Molecular genetic evaluation of myeloproliferative neoplasms.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cellsIntegrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.Mutant BCR-ABL clones in chronic myeloid leukemia.Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.Tumour molecular profiling for deciding therapy-the French initiative.Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
P2860
Q27004032-5985D27D-DDA2-42F7-9B48-D83A60CA0E4BQ28482070-E98284C1-B679-4F03-8218-2309B0722D68Q33885637-42FBB132-78BA-4999-959F-012844443BBEQ33903030-ACDF3066-0FCA-424B-BB92-E9253A0AB025Q34277769-711951AE-B479-442C-BDDA-70E49C14C922Q34522810-D824E2CB-AA3F-4E72-B2B0-28706233D71CQ34894883-ACDE9FF4-C69F-4E13-B31A-6AC1AAF7D8ECQ35106637-264303F9-5AA9-4234-AF6A-275E30FD4FB4Q35117747-1F9A4AC2-5BB7-43AE-93F5-61221D776141Q35221071-76AC02BF-B0A3-44F2-867A-8708E71A8C00Q35652844-4F2D0E0B-0D63-42FE-BAB5-DC16904BACEAQ36081175-F22E9CF4-4E4B-4A82-9EFA-CC7F3693EF28Q36547224-B85C02A1-2FEC-401E-AFD3-6E91E203EF01Q36852243-2F4C5C66-6348-4381-8949-1B86814CC5BCQ36939131-32316660-267A-49ED-BF07-076602CEC458Q37974490-6EBB4FE3-879D-4824-83FA-5AD0564235D9Q38004075-3E45C030-F34F-4ED8-8801-6B92F86DB748Q38172586-B72E7FB3-1B07-4EC2-8A1E-C2FA6AA02934Q38204330-326D1C36-8F43-401B-AF4D-EA6C4B4557EAQ38481945-E9434573-BC33-4FFB-AFC7-83D319411FF0Q38598820-4FFA2D96-E467-40FC-B80A-DD9E11BFF254Q38698520-87BA4A02-D8A7-4C6B-8591-38315D2E64E0Q38771802-3F47D950-A21C-41C9-8E47-30A23B967332Q39092605-DCCA1733-D58C-49EB-98FE-3BDEDF02A460Q40957470-20A09227-62C0-48D8-BCB0-6D6AFB3D9E3FQ40996735-8A50F4D2-32A4-412B-A1D8-AE48F3D34513Q42638910-2B6A3132-9399-4DB7-8781-72FEEB045210Q47705734-9C8BEAEA-D29B-4CA0-AD5D-AFB1FA9D88ABQ50929302-793B3F05-3F09-4BAB-917F-4DC5D5B22606Q54310937-0411B13B-0C28-4E2D-A659-75B87DD26521Q54317762-9F24B409-5AE9-4FE4-BE17-8AF4A9613022Q55026417-2A1CECC5-33A7-433D-9CE4-C62D960BFB9AQ58727408-4A5B710B-FA7A-4A72-A6AE-832D9B7B9082
P2860
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Practical advice for determini ...... with chronic myeloid leukemia.
@ast
Practical advice for determini ...... with chronic myeloid leukemia.
@en
type
label
Practical advice for determini ...... with chronic myeloid leukemia.
@ast
Practical advice for determini ...... with chronic myeloid leukemia.
@en
prefLabel
Practical advice for determini ...... with chronic myeloid leukemia.
@ast
Practical advice for determini ...... with chronic myeloid leukemia.
@en
P2093
P2860
P50
P356
P1433
P1476
Practical advice for determini ...... with chronic myeloid leukemia.
@en
P2093
Giuseppe Saglio
Susan Branford
P2860
P304
P356
10.1002/CNCR.25717
P407
P577
2010-11-29T00:00:00Z